魏佳

研究员、博士生导师
jia_wei@bjmu.edu.cn
北京市海淀区学院路38号
北京大学

魏佳博士，现任北京大学公共卫生学院助理教授、研究员、博士生导师。2019年毕业于北京大学医学部，获学士学位；2023年毕业于牛津大学医学系（Nuffield Department of Medicine）获得Clinical Medicine博士学位，研究方向为传染病与健康数据科学，导师为David Eyre教授和Sarah Walker教授。2023年至2025年在牛津大学从事博士后研究。2024年入选国家海外高层次人才计划青年项目。近年来在Nature Medicine，Nature Microbiology，Nature Communications，Clinical Infectious Diseases等国际高水平期刊上发表学术论文，并担任Journal of Infection, eBioMedicine, Signal transduction and targeted therapy等学术期刊的审稿人。欢迎公共卫生、流行病学、数据科学、儿科学、传染病等领域的学者医生共同合作交流。

主要研究方向

结合流行病学、统计学、传染病学、免疫学与健康数据科学等多学科交叉技术，聚焦于新发突发传染病的流行病学，以及基于临床医疗大数据的传染病与临床流行病学研究。

主要研究领域包括：

1. 儿少妇幼等重点人群的传染病监测、防控与免疫接种

2. 基于纵向队列数据的呼吸道传染病的血清流行病学建模

3. 真实世界研究中的疫苗有效性评估及保护性免疫关联值

4. 肺炎等感染性疾病的临床诊断与抗生素合理使用

5. 基于临床医疗大数据的疾病预测模型构建

课题组长期招募研究助理、博士生、博士后，欢迎对传染病流行病学、临床大数据分析、儿少妇幼卫生等方向感兴趣的同学发送邮件联系。

代表性科研项目

10篇代表性论文

1. Wei J, Pouwels KB, Stoesser N, et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nature Medicine. 2022, 28(5), 1072-1082.

2. Wei J, Stoesser N, Matthews PC, et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nature Microbiology. 2021, 6(9), 1140-1149.

3. Wei J, Matthews PC, Stoesser N, et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. Nature Communications. 2021, 12(1), 6250.

4. Wei J, Matthews PC, Stoesser N, et al. SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection. Nature Communications. 2022, 13(1), 3748.

5. Wei J, Matthews PC, Stoesser N, et al. Protection against SARS-CoV-2 Omicron BA. 4/5 variant following booster vaccination or breakthrough infection in the UK. Nature Communications. 2023, 14(1), 2799.

6. Wei J, Stoesser N, Matthews PC, et al. Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population. Nature Communications. 2024, 15(1).

7. Lumley SF, Wei J, O’Donnell D, et al. The duration, dynamics, and determinants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses in individual healthcare workers. Clinical Infectious Diseases. 2021, 73(3), e699-e709.

8. Wei J, Uppal A, Nganjimi C, et al. No evidence of difference in mortality with amoxicillin versus co-amoxiclav for hospital treatment of community-acquired pneumonia. J Infect. 2024, Jun;88(6):106161.

9. Wei J, Zhou J, Zhang Z, et al. Predicting individual patient and hospital-level discharge using machine learning. Commun Med, 2024, 4, 236.

10. Wei J, Yuan K, Luk A, Walker AS, Eyre DW. Community-acquired pneumonia identification from electronic health records in the absence of a gold standard: A Bayesian latent class analysis. PLOS Digital Health. 2025, 4(7).